Performance in Delivering Clinical Trial Research Q4 2015 - 2016
Time to Target (Commercial Contracts)

Research Ethics Number	Name of Trial	Agreed Target of patients	Total Recruited by Agreed Target Date	Recruitment end date	Trial Status	Target met	Comments
10/H0606/69	RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics	6	4	08/05/2013	Study Complete	No	Four participants recruited from six, viewed as successful by the sponsor because the study has proven difficult to recruit to across all UK sites. In addition the projected recruitment target for this site was probably over ambitious.
10/H0604/94	RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics. Protocol No. NN25307	6	1	30/06/2013	Study Complete	No	This study has proven difficult to recruit to across all UK sites. In addition the projected recruitment target for this site was probably over ambitious.
11/SC/0383	Evaluation of the effects of agomelatine (25mg and 50mg) and escitalopram 20mg during 8 weeks on emotional blunting, emotional processing and motivation in healthy male and female volunteers.	64	64	22/03/2013	Study Complete	Yes	
12/SC/0213	Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of LuAA21004 on cognition and BOLD fMRI signals in subjects remitted from depression and controls	32	30	05/04/2013	Study Complete	No	The study team were unable to recruit the final 2 controls and another UK site (Manchester) agreed to do this. The study recruited the target in the UK. 30 participants out of 32 equates to 94% recruitment.
12/SC/0544	A randomised, double-blind, placebo-controlled, dose-ranging, parallel-group, phase 2 study of the safety and efficacy of ABT-126 in the treatment of cognitive deficits in schizophrenia (CDS) in nonsmokers	6	2	03/01/2014	Study Complete	No	The study has proven difficult to recruit to across all UK sites due to strict inclusion criteria.
12/NE/0410	A randomised, placebo-controlled, parallel-group, double-blind, efficacy and safety trial of MK-8931 in subjects with mild to moderate Azheimer's disease	10	10	31/10/2015	Recruitment Complete	Yes	
12/EM/0391	A randomised, double blind, placebo controlled, phase 3 study to evaluate the efficacy and safety of once a day, TAK375 (Ramelteon) tablet for sub-lingual administration (TAK375SL tablet) 0.1mg and 0.4mg as an adjunctive therapy in the treatment of acute depressive episodes associated with Bipolar 1 disorder in adult subjects	10	4	05/11/2014	Withdrawn	No	Sponsor closed the study early following interim analysis and recommendation from the DMC that the pre-determined efficacy criteria for study termination had been met.
13/SC/0386	Long term safety and efficacy of ABT-126 in subjects with schizophrenia: a double-blind extension study for subjects completing study M10-855	6	1	31/03/2015	Study Complete	No	Only 1 participant was eligible to proceed to the extension study. The 2nd potentially eligible participant withdrew consent to enter the extension study.
13/NW/0727	A randomised, double-blind, placebo-controlled, single-dose, study of the effects of SEP 363856 and Amisulpride on bold-FMRI signal in healthy male and female volunteers with high or low schizotype characteristics	54	50	07/07/2015	Study Complete	No	A high screen failure rate following consent was higher than expected; due mainly to difficulty in identifying potential participants. ie many of the potential participants who seemed to fulfil the inclusion criteria on pre-screening failed at the screening visit. Towards the end of recruitment a new method for identifying this group was ethically approved and was successful; research staff thought the target recruitment was achievable with an extension to the study, however the sponsor declined this.